HER2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signaling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
|Immunogen:||A peptide corresponding to the C-terminus of Human c-erbB-2/HER-2|
|Synonyms:||Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, CD340, HER2, NEU, NGL, c-ErbB-2|
|Observed MW:||Refer to figure|
|Specificity:||This antibody reacts to Human c-erbB-2/HER-2. It may also react to mouse or rat c-erbB-2/HER-2, as predicted by immunogen homology. No cross reactivity with EGF receptor, HER3 or HER4.|
|Purification Method:||Protein A affinity purified from an animal origin–free culture supernatant|
|Buffer:||50% Glycerol/PBS with 1% BSA and 0.09% sodium azide|
|Storage Conditions:||Stable for 1 year at -20.0°C from date of receipt.|
FOR RESEARCH USE ONLY. NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE.